(VIANEWS) – SPAREBANKEN SØR (SOR.OL), ING GROEP N.V. (INGA.AS), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPAREBANKEN SØR (SOR.OL)
33.4% sales growth and 9.48% return on equity
Sparebanken Sør operates as an independent financial institution in Norway. It operates through two segments, Retail Market and Corporate Market. The company is involved in banking, securities trading, and real estate brokerage activities in Agder, Rogaland, Vestfold, and Telemark counties. It also provides leasing, mortgage, and property management services; and sells general insurance, occupational pension, and group life insurance products. The company was founded in 1824 and is headquartered in Kristiansand, Norway. Sparebanken Sør operates as a subsidiary of Sparebankstiftelsen Sparebanken Sør.
Earnings Per Share
As for profitability, SPAREBANKEN SØR has a trailing twelve months EPS of kr13.65.
PE Ratio
SPAREBANKEN SØR has a trailing twelve months price to earnings ratio of 9.3. Meaning, the purchaser of the share is investing kr9.3 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.48%.
More news about SPAREBANKEN SØR.
2. ING GROEP N.V. (INGA.AS)
24.2% sales growth and 25.17% return on equity
ING Groep N.V., a financial institution, provides various banking products and services in the Netherlands, Belgium, Rest of Europe, North America, Latin America, Asia, and Australia. It operates in six segments: Retail Netherlands, Retail Belgium, Retail Germany, Retail Other, Wholesale Banking, and Corporate Line Banking. The company accepts various deposits, such as current and savings accounts. It also offers business lending products; consumer lending products, such as residential mortgage loans, term loans, and other consumer lending loans; and secured and unsecured lending services. in addition, the company provides debt capital market, working capital solutions, export finance, daily banking, treasury and risk, and corporate finance solutions; and specialized lending, debt and equity market solutions, payments and cash management, and trade and treasury services, as well as savings, investment, insurance, mortgage, and digital banking services; and SME loans. It serves individual customers, corporate clients, and financial institutions. ING Groep N.V. was founded in 1762 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ING GROEP N.V. has a trailing twelve months EPS of €1.37.
PE Ratio
ING GROEP N.V. has a trailing twelve months price to earnings ratio of 9.68. Meaning, the purchaser of the share is investing €9.68 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.17%.
Yearly Top and Bottom Value
ING GROEP N.V.’s stock is valued at €13.27 at 22:20 EST, under its 52-week high of €13.55 and way higher than its 52-week low of €8.43.
Sales Growth
ING GROEP N.V.’s sales growth is 21.9% for the current quarter and 24.2% for the next.
Moving Average
ING GROEP N.V.’s worth is way higher than its 50-day moving average of €11.38 and way above its 200-day moving average of €11.14.
Revenue Growth
Year-on-year quarterly revenue growth grew by 51.8%, now sitting on 31.29B for the twelve trailing months.
More news about ING GROEP N.V..
3. NAVAMEDIC (NAVA.OL)
22.8% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.73.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 21.45. Meaning, the purchaser of the share is investing kr21.45 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr37.10 at 22:20 EST, way below its 52-week high of kr43.60 and way above its 52-week low of kr27.80.
More news about NAVAMEDIC.
4. SONAECOM,SGPS (SNC.LS)
19.6% sales growth and 5.08% return on equity
Sonaecom, S.G.P.S., S.A., together with its subsidiaries, operates in technology, media, and telecommunications areas worldwide. The company provides consultancy services in the area of information systems; sells licensed software; and research, development, consulting, maintenance, and audit services for products, systems, facilities, and communication and security services. It also engages in the editing, composition, and publication of periodical and non-periodical materials, as well as exploration of radio and TV stations and studios; consulting, advisory, audit, and maintenance of various facilities, and communication services and security systems; and purchase and installation of communication and security systems. In addition, the company is involved in the research, development, and commercialization of projects and service solutions in the area of information technology, communications and retail, and consulting activities for business and management; development, installation, implementation, training, and maintenance of systems and software products; rental of equipment; consulting business; industries and trade of electronic equipment and software; and advisory in retail segments, and industries and services. Further, it provides support, management consulting, and administration, primarily in the areas of accounting, taxation, administrative procedures, logistics, human resources, and training; and services in IT and cybersecurity to institutions, banks, and insurance companies, as well as invests in and manages venture capital and venture capital funds. The company was founded in 1988 and is headquartered in Cidade da Maia, Portugal. Sonaecom, S.G.P.S., S.A. is a subsidiary of Sontel B.V.
Earnings Per Share
As for profitability, SONAECOM,SGPS has a trailing twelve months EPS of €0.21.
PE Ratio
SONAECOM,SGPS has a trailing twelve months price to earnings ratio of 11.67. Meaning, the purchaser of the share is investing €11.67 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Yearly Top and Bottom Value
SONAECOM,SGPS’s stock is valued at €2.45 at 22:20 EST, way below its 52-week high of €2.75 and way higher than its 52-week low of €1.72.
Volume
Today’s last reported volume for SONAECOM,SGPS is 817 which is 83.37% below its average volume of 4915.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SONAECOM,SGPS’s EBITDA is 21.58.
More news about SONAECOM,SGPS.
